Sign in
Taking people in United StatesEarly phase 1

Testing Oral Ketone Esters in People With Heart Failure and Diabetes

Tests a ketone drink on heart function in adults with diabetes and heart failure.

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Registry title
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
Status
Recruiting
Phase
Early phase 1
People taking part
10 people, planned
Started
16 Jan 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Ketone Monoester (KE)
Record updated
21 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with type 2 diabetes and heart failure with reduced ejection fraction. It tests oral ketone esters.

Age
18 to 80 years
Sex
All sexes
Disease stage
Heart failure diagnosed before screening and shown on imaging in the last 6 months. HbA1c 6.0-10.0% (42–86 mmol/mol). eGFR above 30 ml/min•1.73 m2. Blood pressure below 145/85 mmHg. BMI 23-38 kg/m2.
Earlier treatment
Must be on a stable dose of guideline-directed heart failure medicines. Cannot have been treated with SGLT2 inhibitors or medicines that may impair heart function or acutely worsen blood sugar control.

Main reasons for not taking part

  • Pregnancy, breastfeeding, or plans to become pregnant
  • Cardiovascular event in the last 3 months
  • History of cancer (except basal or squamous cell cancer in remission for 5 years)
  • Allergy or sensitivity to study drugs or their ingredients
  • Current drug or alcohol use or dependence that would interfere with the study

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Subjects must be on a stable dose of guideline-directed medications for Heart Failure (HF)
  • Patients will have an established diagnosis of HF before the screening visit, documented by an acceptable imaging modality in the last 6 months
  • Age = 18-80 y
  • Body Mass Index (BMI) =23-38 kg/m2
  • Glycated hemoglobin (HbA1c) = 6.0-10.0%
  • Blood Pressure (BP) < 145/85 mmHg
  • Estimated Glomerular Filtration Rate (eGFR) > 30 ml/min•1.73 m2
  • For women of child-bearing age (WOCBA) willingness to use contraception, if applicable

Who cannot take part

  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • Allergy/sensitivity to study drugs or their ingredients
  • Subjects with a history of cancer (except basal or squamous cell cancer that has been resolved/remission for 5 years)
  • Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study
  • Patients treated with Sodium-Glucose Transport Protein (SGLT2i's) or medications that may impair heart function or acutely worsen glycemic control will be excluded
  • Pregnancy, lactation, or plans to become pregnant. A negative pregnancy test will be performed before each Magnetic resonance imaging (MRI) study to assess current status
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent
  • Cardiovascular event within the last 3 months

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Carolina Solis-Herrera, MDTaking people

About the trial

What the trial wants to find out

This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

The group in the trial

  • Ketone Ester administrationTreatment being tested

    1. Monitored administration of oral Ketone monoester at 400mg/kg dosed twice on visit 2 (cardiac MRI day) 2. Self administered oral β-hydroxybutyrate (BOHB) at 400mg/kg/day for a period of 6 days

    Treatment: Ketone Monoester (KE)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
Plain-language title
Testing Oral Ketone Esters in People With Heart Failure and DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06108076, who can take part
Record updated
21 January 2026